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Aim To assess the causes of early death (ED) and late death 
(LD) in patients with systemic lupus erythematosus (SLE) 
and determine the features of deceased SLE patients fol-
lowed-up in a single Croatian tertiary hospital center, be-
cause little if any data on causes of death (CODs) in SLE 
patients are available for Croatia.
Method We identified SLE patients regularly followed-up 
at the Division of Clinical Immunology and Rheumatology, 
University Hospital Center Zagreb, who died from 2002 to 
2011. Death was ascertained by matching our institution-
al records with the Croatian National Death Database. Pa-
tients were grouped according to their disease duration to 
ED and LD and compared by demographic characteristics, 
classification criteria, organ damage, and CODs.
Results We identified 90 patients (68 women), who died 
at the age of 58 ± 15 years. The most frequent COD cate-
gory was cardiovascular diseases (40%), followed by infec-
tions (33%), active SLE (29%), and malignancies (17%). No 
significant difference was found between the frequencies 
of causes of ED and LD, except for stroke, which caused 
only LD≥10 years after the diagnosis. SLE was reported in 
death certificates of only 41 of 90 patients.
Conclusion Although stroke occurred both in the early and 
late disease course, it was primarily associated with LD. Giv-
en the low proportion of SLE recorded in death certificates 
of deceased SLE patients, matching of institutional and vital 
statistics records may be required to assess the true impact 
of SLE on mortality.
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The disease course and causes of death in patients with 
systemic lupus erythematosus (SLE) are characterized by 
a complex interplay of the systemic disease itself and a 
number of comorbidities (1). In the 1970s, Urowitz et al (2) 
described a bimodal pattern of mortality in SLE patients, 
with active disease and infections as leading causes of ear-
ly death and cardiovascular diseases as the major cause of 
late death. A similar pattern was observed in their prospec-
tive study of 51 patients one decade later (3).
However, the bimodal pattern has not been unequivocally 
recognized in the new millennium. It was confirmed in a 
large multicenter Chinese study (4), but not in the Euro-
pean multicenter study of causes of death (5). Nonethe-
less, concepts of early and late death remain generally ac-
cepted. Five years after SLE diagnosis and/or meeting the 
classification criteria, primarily those of the American Col-
lege of Rheumatology (ACR), have been a provisional time 
point accepted as a cut-off between early and late death 
in previous studies (5-9).
Over the last four decades, a tremendous improvement in 
outcomes of SLE has been observed both in Europe and 
worldwide. Increase in a 5-year survival from 50% to over 
90% and the achievement of 10-year survival exceeding 
90% redirected the focus of interest toward the features of 
long-term disease, including causes of late death (5,9-11).
Most data on SLE outcomes in Europe are derived from 
studies conducted in established cohorts of SLE patients in 
highly developed countries with health care systems able 
to support dedicated lupus centers. However, SLE is a dis-
ease with pronounced phenotypic differences between 
geographically, ethnically, and socio-economically different 
populations. Given a relatively loose SLE definition, reliance 
on clinicians’ evaluation, no diagnostic criteria, and a set of 
classification criteria that include only the most specific fea-
tures of SLE, these differences are even more pronounced 
than those related to some other disorders, such as arterial 
hypertension, coronary heart disease, or asthma. Although 
our Center participated in the aforementioned multicenter 
European study on causes of death (5), little if any data are 
available on the outcomes of SLE in Croatia and neigh-
boring central and southeastern European countries and 
causes of death and features of deceased SLE patients from 
Croatia have never been specifically analyzed.
Our aim was to assess causes of death and disease features 
in SLE patients followed-up regularly in our institution 
who died over a 10-year period, with an emphasis on 
differences between early and late death. Our hypothesis 
was that active disease and infections were more frequent 
causes of early death, whereas cardiovascular diseases and 
malignant tumors more frequently caused late death.
PATIENTS AND METHODS
Patients
This retrospective observational study included patients 
with SLE who visited the Division of Clinical Immunolo-
gy and Rheumatology, University Hospital Center Zagreb, 
at least once between January 1, 2002 and December 31, 
2011. The Division serves as the leading academic center 
dedicated to connective tissue diseases and SLE in Croatia. 
Of all SLE patients who visited the Division, we identified 
regularly followed-up patients who died in the study period 
and who were Croatian residents at the time of death, ful-
filled ≥4 ACR criteria (6,7), and had a known year of diagno-
sis (Figure 1). A patient was considered to be regularly fol-
lowed-up if the last visit to our institution had been within 
three years before death (12). We excluded patients with an 
overlap of SLE and another systemic autoimmune disease.
The patients were included in the early death (ED) group 
if death occurred in the early disease course and in the 
late death (LD) group if death occurred in the late disease 
course. Disease duration was defined as time from diag-
nosis to death. Two cut-off points between early and late 
death were used, ie, five and ten years after diagnosis, as 
proposed by Nossent et al (5).
Data sources and collection
Data were extracted from medical charts stored at the Di-
vision since 1978 and from the Division’s computer data-
base of SLE patients, containing demographic data and 
main disease features. The deceased patients were identi-
fied by matching the Division’s database with the National 
Death Database administered by the Croatian Institute of 
Public Health. The National Death Database contains data 
on a single cause of death for each patient who died after 
2002. Causes of death were identified from medical charts 
and from the National Death Database. They were also ob-
tained from primary care physicians and by direct contact 
with family members, when available.
Distance between the patients’ residence (home address) 
and our institution (in kilometers) were obtained by de-
termining the shortest route provided by the internet-
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based service Google Maps (Google LLC, Mountain View, 
California, USA).
For each patient, we collected demographic data, num-
ber of ACR criteria met at diagnosis and time of death (6,7), 
damage according to the Systemic Lupus International 
Collaborating Clinics (SLICC)/ACR damage index (SDI) one 
year after diagnosis as an indicator of early damage and 
cumulatively at time of death (13), causes of death, and 
medications.
Data on ACR criteria met at diagnosis were missing for 17 
of 90 patients (Supplementary Material 1). Causes of death 
were grouped into categories most frequently mentioned 
in the literature as follows: active lupus, infections, car-
diovascular diseases, and malignant tumors (5,8,9,14,15). 
Death was attributed to active lupus provided there was 
clinical or post mortem evidence of active disease (16). 
More than one cause of death was possible in a single pa-
tient; however, the cause of death was unknown in 8 of 
90 patients. Medications included glucocorticoids and im-
munosuppressive agents such as oral cyclophosphamide, 
intravenous cyclophosphamide pulses, cyclosporine A, 
azathioprine, and mycophenolate mofetil. Data on the 
treatment with warfarin and acetylsalicylic acid were col-
lected for patients who died from stroke.
FIguRE 1. Flow diagram of selection of patients with systemic lupus erythematosus (SLE) from 2002 to 2011. Dotted two-way arrow 
indicates comparison of early and late death. Meeting ≥4 American College of Rheumatology (ACR) criteria was used as a cut-off for 
classification of SLE patients according to the criteria definition. Abbreviations: N – number of patients; M – number of males; F – 
number of females; dg – diagnosis; f/u – follow-up; y – years; SLE + overlap – patients with a diagnosis of SLE and another systemic 
autoimmune disease.
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Statistical analysis
Continuous data were presented descriptively as mean 
and standard deviation (SD) or median and interquartile 
range (IQR). Categorical variables were presented as pro-
portions or frequencies.
Data were compared between the ED and LD groups. As 
an exception, proportions or frequencies of patients treat-
ed with glucocorticoids and immunosuppressive agents 
were compared between patients who died due to an in-
fectious cause and patients who died due to a non-infec-
tious cause.
The Kolmogorov-Smirnov test was used to test for normal-
ity of distribution. Normally distributed continuous vari-
ables were compared using the Student t-test, whereas the 
Mann-Whitney U-test was used in other cases. Categorical 
variables were compared using the χ2 test and Fisher ex-
act test. As an exception, comparison of damage accrual 
during the first year after diagnosis and the annual accrual 
of damage during further follow-up (both variables non-
normally distributed) was performed using the Wilcoxon 
signed rank test, suitable for paired observations.
P values less than 0.05 were considered statistically signifi-
cant except in cases of adjustment for multiple compari-
sons, where the cut-off for statistical significance was de-
creased according to the Holm-Bonferroni method (17).
Correlation between the disease duration defined as time 
from SLE diagnosis to death and distance between patient 
place of residence and our institution was presented using 
the Spearman’s rank correlation coefficient (due to a non-
normal distribution of the correlated data) with 95% confi-
dence interval (CI).
Statistical analyses were performed using Statistica ver. 12 
(Dell, Round Rock, Texas, USA; license issued to the School 
of Medicine, University of Zagreb), except for the distribu-
tion of mortality and the existence of its (bi)modal pattern, 
which was analyzed using the Joinpoint Regression Pro-
gram version 4.2.0.2 (National Cancer Institute, Bethesda, 
MD, USA) (18).
RESuLTS
From 2002 to 2011, a total of 967 SLE patients visited the 
Division. Of them, 149 died during the 10-year period. The 
study criteria were met by 90 patients, of whom 21 died 
within five and 43 within 10 years after diagnosis (Figure 1).
Demographic characteristics
There were three times more women than men among 
the SLE patients included in our study (Table 1). The mean 
age at death for all patients was ≤60 years, with no differ-
ence between the ED and LD groups. Patients in the ED 
group were diagnosed at an older age than patients in the 
LD group. The mean disease duration was 10.6 ± 7.7 years. 
Joinpoint regression revealed zero joinpoints, yet only a 
slightly declining trend in the number of deaths that oc-
curred as a function of time elapsed from diagnosis (Figure 
2). In other words, a (bi)modal pattern was not observed.
The median distance between patient place of residence 
(home address) and our clinic was 46.8 km (IQR 9.9-104.5 
km). Among the 90 deceased patients, there was no cor-
TABLE 1. Characteristics of 90 patients with systemic lupus erythematosus who died between 2002 and 2011*















Women-to-men ratio  3.09  4.25  2.83  0.511  3.78  2.62  0.458
Age at diagnosis (years; mean±SD) 47.5 ± 16.9 56.4 ± 15.0 44.8 ± 16.6  0.005 55.7 ± 15.2 40.1 ± 15.0 <0.001
Age at death (years; mean±SD) 58.1 ± 14.8 58.4 ± 14.7 58.0 ± 14.9  0.914 60.3 ± 15.2 56.2 ± 14.3  0.187
Home-to-clinic distance (km; median, IQR) 46.8 (9.9-104.5) 49.8 (15.0-103.0) 41.9 (9.1-107.0)  0.501 49.8 (9.4-106.0) 41.5 (10.1-104.0)  0.796
Number of met ACR criteria (median, IQR)
at diagnosis  4 (3-5)  4 (4-5)  4 (3-5)  0.038  4 (4-5)  3.5 (3-4)  0.009
at death  6 (5-7)  5 (4-6)  6 (5-7)  0.018  5 (4-6)  6 (5-7)  0.046
SDI (median, IQR)
at 1 year after diagnosis  1 (0-2)  2 (1-3)  0 (0-1)  0.005  1 (0-3)  0 (0-1) <0.001
at death  5 (3-7)  3 (1-4)  5 (3-8) <0.001  3 (1-5)  7 (4-9) <0.001
*Abbreviations: SD – standard deviation, IQR – interquartile range, ACR – American College of Rheumatology, SDI – Systemic Lupus Erythematosus 
International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index.
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relation between the home-to-clinic distance and disease 
duration (Spearman’s rank correlation coefficient -0.1223, 
95% CI -0.327 to 0.093).
Disease features according to ACR criteria
In comparison with patients in the ED group, those in the 
LD group met a higher number of criteria at the time of 
death. Conversely, the number of criteria fulfilled at diag-
nosis was higher in the ED group (Table 1).
The most frequent classification criteria observed among 
deceased patients both at diagnosis and cumulatively were 
related to the laboratory features of SLE and included anti-
nuclear antibodies (ANA) and immunologic and hemato-
logic disorders (Figure 3). immunologic disorder was mostly 
driven by the presence of anti-double stranded DNA (anti-
dsDNA) antibodies (79%), whereas hematologic disorder 
(83% cumulatively) was primarily driven by lymphopenia 
(64%) and leukopenia (49%). The most frequent clinical 
feature was arthritis (70% cumulatively). Despite the differ-
ences in the total number of criteria, no difference was ob-
served between the ED and LD groups in the frequency of 
individual criteria (supplementary material 1).
Damage according to the SDI
Patients in the LD group accrued more damage over the 
course of disease than patients in the ED group, although 
their damage was lower one year after diagnosis (Table 
1). Only 5 of 90 patients had no damage accrual over the 
entire disease course. Four of these patients died within 
five years, whereas the fifth patient died nine years after 
diagnosis. One year after diagnosis, damage accrual (early 
damage) was observed in 14 of 17 patients deceased with-
in five years, 15 of 22 deceased 5-10 years after diagnosis, 
and only 19 of 47 patients deceased after ≥10 years. In the 
group of patients who died within five years after diagno-
sis, the denominator is 17 rather than 21, because four pa-
tients died in less than a year after diagnosis.
The most frequently observed components of the SDI, 
both at death and one year after diagnosis, were musculo-
skeletal, cardiovascular, and neuropsychiatric damage (Fig-
ure 4). Comparison of individual components of the SDI 
revealed a higher proportion of cumulative musculoskel-
etal damage in patients deceased ≥5 years after diagnosis 
(48 of 69 patients) compared to those deceased <5 years 
after diagnosis (5 of 21 patients; P < 0.001). It also revealed a 
higher proportion of cardiovascular damage one year after 
diagnosis in patients deceased <10 years after diagnosis 
compared to patients deceased thereafter (13 of 39 vs 2 of 
47 patients; P < 0.001) (supplementary material 2). Major-
ity of the (sub)components of the SDI were observed in at 
least one patient within a year after diagnosis (supplemen-
tary material 3).
In all patients, damage accrued during the first year af-
ter diagnosis of SLE (median 1, IQR 0-2) exceeded annual 
damage accrual over the following disease course (medi-
an 0.33, IQR 0.09-0.51) (P < 0.001, Wilcoxon sum of signed 
ranks equaling 1685).
FIguRE 2. Distribution of mortality in 90 patients with systemic lupus erythemato-
sus (SLE). A (bi)modal pattern was not confirmed. Number of patients refers to the 
patients deceased at a time point of X years after SLE diagnosis.
FIguRE 3. Distribution of the American College of Rheumatology classification criteria 
in 90 patients with systemic lupus erythematosus at the time of diagnosis (gray bars) 
and time of death (black bars).
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Causes of death
No difference was observed in the frequencies of causes 
of death between the ED and LD groups irrespective of 
whether the 5- or 10-year cut-off was used (Table 2). The 
exception was stroke, which caused death only ≥10 years 
after diagnosis, even though patients in the ED group also 
developed stroke as a component of damage during the 
course of their disease.
Despite no difference in the observed frequencies, a dif-
ference in their sequence could be seen between patients 
deceased within and after five years following diagnosis. 
While infection and active disease were the most frequent 
causes of death in patients deceased within five years, car-
diovascular diseases were the leading cause in patients de-
ceased after five years following diagnosis.
Among 26 patients that succumbed to active lupus, 17 
patients had multiorgan activity (≥2 organs affected), six 
had active renal disease, two had active neurolupus, and 
a single patient had vasculitis. There was a notable overlap 
between disease activity and infection, with 14 of 26 pa-
tients also having infection reported as a cause of death. 
Furthermore, 4 of 8 patients deceased due to stroke also 
died from active lupus.
All 30 patients who deceased due to infections were treat-
ed with glucocorticoids during their disease course, where-
as 22 of them also received immunosuppressive agents 
(11 patients received oral cyclophosphamide, 7 received 
cyclophosphamide intravenous pulses, 11 received azathi-
oprine, 3 received cyclosporine A, and 1 patient received 
mycophenolate mofetil). Similar proportions, but without 
statistically significant differences in comparison with the 
previous 30 patients, were observed in the remaining 60 
patients who died due to non-infectious causes. Of these 
60 patients, 59 were treated with glucocorticoids (P = 0.477 
for comparison with the infectious disease group), and 33 
of 60 received immunosuppressant drugs (P = 0.093) includ-
ing oral cyclophosphamide in 17 patients (P = 0.421), cyclo-
phosphamide intravenous pulses in 8 patients (P = 0.230), 
FIguRE 4. Distribution of damage according to the Systemic Lupus International 
Collaborating Clinics/American College of Rheumatology Damage Index (SDI) in 90 
patients with systemic lupus erythematosus 1 year after diagnosis (gray bars) and at 
time of death (black bars).
TABLE 2. Distribution of causes of death in patients with systemic lupus erythematosus according to categories and comparison of 
their frequencies between early and late death





(<5 years) (n = 21)
late death 
(≥5 years) (n = 69) P
early death 
(<10 years) (n = 43)
late death 
(≥10 years) (n = 47) P
Active lupus 26 (29.0) 8 18 0.288 11 15 0.508
Infection 30 (33.0) 9 21 0.290 14 16 0.881
sepsis 20 (22.9) 6 14 0.549 9 11 0.778
pneumonia 18 (20.0) 5 13 0.756 8 10 0.797
urinary tract infection  8 (9.0) 3 5 0.329 5 3 0.472
Cardiovascular disease 36 (40.0) 6 30 0.222 16 20 0.605
ischemic cardiomyopathy  7 (13.0) 1 11 0.281 6 6 0.869
myocardial infarction  5 (6.0) 1 4 1.000 1 4 0.363
stroke  8 (9.0) 0 8 0.190 0 8 0.006
pulmonary embolism  3 (3.0) 1 2 0.554 1 2 1.000
Malignant tumor 15 (17.0) 1 14 0.177 4 11 0.073
Other 10 (11.0) 4 6 NT§ 6 4 NT†
unknown  8 (8.0) 1 7 NT§ 2 6 NT†
*More than one cause possible in a single patient.
†Not tested.
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azathioprine in 25 patients (P = 0.648), cyclosporine A in 3 
patients (P = 0.396), and mycophenolate mofetil in 1 patient 
(P = 1.000). Of 36 patients deceased due to cardiovascular 
disease, 15 succumbed to a thrombotic or thromboembolic 
event, such as stroke, myocardial infarction, and pulmonary 
embolism (Table 2). One patient had both stroke and myo-
cardial infarction listed as causes of death. Among these 
36 patients, six had secondary antiphospholipid syndrome 
(APS), 17 patients were positive for anticardiolipin antibod-
ies (ACLA), and six had a positive lupus anticoagulant (LAC). 
LAC positivity was observed in five patients also having 
positive ACLA. Although antibodies to beta-2 glycoprotein 
I (beta-2-GPI) were found in two patients also positive for 
LAC and ACLA, detection of beta-2-GPI antibodies was not 
routinely available at our institution until 2010. Among 15 
patients deceased due to a thrombotic or thromboembolic 
event, four were diagnosed with secondary APS, six were 
positive for ACLA, two for LAC, and one for antibodies to 
beta-2-GPI. Of eight patients who died from stroke, four 
had been receiving acetylsalicylic acid (ASA) before stroke, 
7 received ASA after the onset of stroke, and 2 were receiv-
ing warfarin. Warfarin had been prescribed before the on-
set of stroke due to episodes of deep venous thrombosis in 
conjunction with positive ACLA. In addition to thrombotic 
or thromboembolic events and ischemic cardiomyopathy, 
other cardiovascular causes of death included heart fail-
ure due to mitral valve insufficiency (2 patients), complete 
atrioventricular block (1 patient), ventricular tachycardia (1 
patient), aortal dissection with cardiac tamponade (1 pa-
tient), hypertensive cardiomyopathy with atrial fibrillation 
(1 patient), sudden cardiac death (2 patients), and heart fail-
ure with cause not specified (6 patients).
Both solid and hematological malignancies were identified 
as causes of death. All were diagnosed after a median of 
10 years (IQR 7-12 years) after SLE diagnosis. A total of 15 
patients (13 women) died due to a malignant tumor. Lung, 
anal, and pancreatic carcinomas caused death in two pa-
tients each, whereas mesenterial non-Hodgkin lymphoma, 
myeloproliferative syndrome, prostatic, breast, bladder, 
renal, ovarian, cervical, and colorectal carcinoma caused 
death in a single patient each. In this group of patients 
SLE was diagnosed at a mean age of 46 ± 14 years. Base-
line data on ACR criteria met at diagnosis of SLE were avail-
able for 13 of these 15 patients and included malar rash 
(7 patients), discoid rash (3 patients), photosensitivity (7 
patients), and arthritis (5 patients). Antinuclear antibodies 
were positive in 10, antibodies to double-stranded DNA in 
6, and ACLA in 2 patients. Leukopenia was detected in 3 
of the 13 patients as the only hematological feature. Con-
versely, renal (proteinuria and urinary cellular casts) and 
neuropsychiatric disorder (psychosis) were observed each 
in a single patient, while serositis was not observed at di-
agnosis of SLE in any of the 13 patients.
Autopsy was performed in 17 of 90 patients. SLE was re-
ported in the death certificate of only 41 of 90 patients. Of 
90 deceased patients, 63 died in the hospital setting, 23 at 
home, and 4 in a retirement home.
DISCuSSION
No difference was found in the frequencies of causes of 
death between the ED and LD groups. Therefore, our hy-
pothesis was not confirmed. The only exception was stroke 
that caused exclusively late death. Because stroke was also 
observed in patients who died earlier, although not as a 
cause of death, stroke occurring ≥10 years after diagno-
sis may be associated with increased mortality. Despite the 
prevailing perception of stroke as a consequence of ath-
erosclerosis (19), disease activity may also play a role in its 
development (20).
The difference in the sequence of causes of death be-
tween patients deceased within and after five years is con-
sistent with the perception that infection and active SLE 
are causes of early death and cardiovascular diseases are 
causes of late death (2,21). However, our analysis did not 
confirm the bimodal pattern of mortality, but correspond-
ed with an almost linear distribution of mortality as found 
in the multicenter European study by Nossent et al (5). The 
“flattening” of the bimodal curve may be attributed not 
only to better control of the disease, but also to increased 
recognition of patients with less severe SLE. A further simi-
larity to that study is the lack of difference in the frequen-
cies of causes of early and late death, except for active SLE 
that was a more frequent cause of early death in the study 
by Nossent et al (5). Similar to our study, stroke caused 
only late death in the Korean study by Kang et al (8) and 
the British study by Moss et al (9). Except for stroke, Ko-
rean patients had no other atherosclerosis-related causes 
(8), which is in contrast to European populations, but con-
sistent with other studies of SLE in Asian patients (16,22). 
Pulmonary hypertension caused death in a noticeable pro-
portion of Korean patients (8) as opposed to European pa-
tients (5,9,14,23). Malignant tumors were more frequently 
observed in our study than in two European multicenter 
studies (5,14), and especially the Korean study where 
only one patient succumbed to malignant disease (8). 
The proportion of malignancies in our study was 
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similar to proportions seen in two cohorts in the United 
Kingdom (9,23).
Although the proportion of unknown causes was up to 
10% in our study and two previous studies (5,9), it exceed-
ed 20% in the Euro-lupus project (14). The finding by Moss 
et al (9) that all patients with an unknown cause of death 
died >5 years after diagnosis may signal a contribution of 
disease duration and loss to follow-up to losing data. Fur-
thermore, the rather low percentage of patients deceased 
outside the hospital in the study by Nossent et al (5) raises 
concerns about underrecognition of out-of-hospital death. 
Due to the relatively high extent of loss to follow-up in SLE 
patients, a linkage with sources of data other than hospital 
charts and death certificates of patients deceased in study 
hospitals seems to be required (8,24,25).
Multiple cause of death analysis (MCDA) may be a useful 
method to assess the mutual impact of different causes 
of death (26). Hitherto, two studies analyzed adult lupus 
mortality using this methodology (27,28). However, MCDA 
does not take into account lupus patients not having SLE 
reported in their death certificates. Underreporting of 
SLE was observed even in two prospective lupus cohorts 
from the United States, where SLE was not listed in 40% of 
death certificates (29). Underreporting was even more pro-
nounced in our study.
Similar to the study by Nossent et al. (5), damage at time of 
death in our study was higher in the LD than in ED group. 
In the aforementioned study, mean damage at late death 
was 7.2, while it was 4 in patients deceased earlier (5). Both 
figures are higher than in our study, despite our patients 
being >10 years older at diagnosis. Possible explanations 
of this difference are higher frequencies of criteria associ-
ated with severe disease in the study by Nossent et al. (5) 
and lower percentage of in-hospital deaths in our study, 
potentially suggestive of less severe disease. Another pos-
sible explanation is that the starting point of follow-up in 
our study was defined as diagnosis of SLE, as it was in the 
study by Kang et al (8), whereas Nossent et al (5) used the 
time of fulfilling ≥4 criteria as the starting point. Although 
the disclosed disease duration in our and two other studies 
was around 10 years (5,8), the actual time elapsed from the 
onset of the first disease symptom was probably longer in 
the study by Nossent et al (5).
In contrast to damage at death, early damage in our 
study was higher in the ED group. This finding may be 
suggestive of a more severe disease course in the ED 
patients (30,31). In comparison with LD group, the mean 
age at diagnosis in the ED group was >10 years higher, 
suggestive of a potential contributing role of comorbidi-
ties related to higher age, many of which may overlap with 
organ damage attributed to inflammation in SLE or glu-
cocorticoid or immunosuppressive treatment. Additional 
effort should be put into screening for comorbidities and 
signs of (early) organ damage in patients diagnosed at a 
later age.
To our knowledge, our study is the first to consistently use 
two cut-offs between early and late death in SLE patients.
The main limitation of our study is its retrospective nature 
based on medical records, which probably led to under-
reporting of clinically relevant events. Different laboratory 
methods were used over the patients’ disease course. We 
were not able to analyze medication doses, disease activity, 
and socioeconomic features. We excluded patients with an 
overlap between SLE and another systemic autoimmune 
disease due to the heterogeneity of their clinical features 
and the problem of their attribution to SLE. We also exclud-
ed patients not seen within three years before death (12). 
Still, this did not prevent us from dealing with the lack of 
data at time of death. Finally, we cannot state that the re-
sults are representative for entire Croatia.
In conclusion, our study did not confirm the bimodal pat-
tern of mortality and found no difference between the fre-
quency of causes of early and late death in SLE patients. 
The role of stroke as a cause of exclusively late death re-
quires elucidation. Matching hospital data with vital statis-
tics databases is required to fully assess the impact of SLE 
on mortality.
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